DT Investment Partners LLC Grows Stock Holdings in Danaher Co. (NYSE:DHR)

by · The Cerbat Gem

DT Investment Partners LLC increased its stake in Danaher Co. (NYSE:DHR – Free Report) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,041 shares of the conglomerate’s stock after buying an additional 72 shares during the period. DT Investment Partners LLC’s holdings in Danaher were worth $289,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tsfg LLC increased its holdings in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. nVerses Capital LLC bought a new stake in Danaher during the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the second quarter worth about $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter valued at approximately $51,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 3.2 %

Shares of NYSE:DHR opened at $247.88 on Friday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a market cap of $183.60 billion, a PE ratio of 42.01, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The stock has a 50 day moving average of $270.43 and a 200 day moving average of $260.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, equities research analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DHR. Evercore ISI boosted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday. Finally, Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Get Our Latest Stock Analysis on DHR

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories